Raymond James & Associates Buys 954 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Raymond James & Associates lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,689 shares of the company’s stock after purchasing an additional 954 shares during the quarter. Raymond James & Associates owned 0.18% of Medpace worth $18,589,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MEDP. Fidelis Capital Partners LLC acquired a new position in shares of Medpace during the first quarter worth $31,000. DT Investment Partners LLC acquired a new position in Medpace in the 2nd quarter worth about $41,000. J.Safra Asset Management Corp raised its position in Medpace by 87.0% in the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of Medpace during the second quarter worth about $52,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Medpace during the first quarter worth about $54,000. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. TD Cowen cut their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday. Truist Financial reduced their price objective on shares of Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. UBS Group lowered Medpace from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. Deutsche Bank Aktiengesellschaft reduced their price target on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research report on Wednesday, July 24th. Finally, Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average target price of $380.00.

Medpace Stock Performance

Shares of MEDP stock opened at $330.22 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $239.00 and a fifty-two week high of $459.77. The stock has a 50 day simple moving average of $351.45 and a two-hundred day simple moving average of $381.28. The company has a market cap of $10.24 billion, a P/E ratio of 28.92, a PEG ratio of 1.74 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.24. The company had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.22 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 11.77 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.